Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaustauf – page 28

349 clinical trials in Donaustauf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaustauf at a glance
349
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

349 trials in Donaustauf

Open in trial search

Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gilead Sciences Inc.

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Study on Tacrolimus Dosing for Stable Adult Kidney Transplant Patients in the First Year After Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Medical University Of Vienna

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Study on Peppermint Oil and Caraway Oil for Patients with Functional Gastrointestinal Disorders

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caraway Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Polycythaemia vera

Not recruiting

Study on Hydroxycarbamide Resistance in Patients with Polycythemia Vera Identified by AI Predictors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:Novartis Pharma GmbH

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Lung adenocarcinoma

Not recruiting

Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of Magrolimab and Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:University of Leipzig

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaustauf

What the registry says about research in the country

01 Pulmonary Research

Clinical investigations focusing on idiopathic pulmonary fibrosis (IPF), a progressive lung condition that affects respiratory function. These trials aim to evaluate new therapeutic approaches for improving lung function in affected patients.

  • Respiratory Function Assessment
  • Treatment Response Evaluation
  • Dose-Response Analysis

Research efforts include comparative studies between various treatment doses and placebo to determine optimal therapeutic effectiveness for patients with pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.